Anatara explores new options as Zoetis terminates Detach deal

摘要

Australian firm Anatara Lifesciences is reviewing strategic options for its animal health assets, after Zoetis cancelled a licensing deal between the two firms.Anatara's Detach is a nonantibiotic animal health asset that aids in the control of diarrheal disease (also known as scours) in piglets. The firm believes Detach has potential in other livestock species, aquaculture and companion animals.